comparemela.com
Latest Breaking News On - Fidanacogene elaparvovec - Page 1 : comparemela.com
FDA Approves One-Time Gene Therapy Fidanacogene Elaparvovec for Hemophilia B
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez; Pfizer), a gene therapy administered in a one-time dose, for certain patients with moderate to severe hemophilia B.
Adam-cuker
Kim-phelan
Hemophilia-thrombosis-program
Hemophiliab-national-organization-for-rare-disorders
Coalition-for-hemophilia
Pfizer
Penn-comprehensive
Updated-september
Gene-therapy
Hemophilia-b
Fidanacogene-elaparvovec
Pfizer's Hemophilia B Gene Therapy Approved as Beqvez in Canada
The FDA and the European Medicines Agency have accepted marketing authorization applications and decisions are pending.
Canada
Linkedin-alfonso-iorio
Alfonso-iorio
Pfizer
Mcmaster-university
European-medicines-agency
Health-canada
Health-research-methods
Pfizer-canada
Specialty-business-unit
Prescription-drug-user-fee-act
Beqvez
vimarsana © 2020. All Rights Reserved.